文献速递淋巴瘤

滤泡性淋巴瘤是否应进行PET引导治疗?

Is it time for PET-guided therapy in follicular lymphoma?
PubMed 文献 · Blood · 2022-01-01

18F-氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描(PET-CT)已成为滤泡性淋巴瘤(FL)分期和疗效评估的金标准成像方式。本文提出PET可指导分期的场景,并指出基线最大标准化摄取值(SUVmax)预测组织学转化尚未被GALLIUM研究证实。诱导结束(EOI)PET对高肿瘤负荷患者的无进展生存和总生存有强预测价值,正被评估为反应适应治疗的平台。

要点

  • PET-CT是FL分期和疗效评估的金标准成像方式
  • 基线SUVmax预测组织学转化未被GALLIUM研究证实
  • EOI PET对高肿瘤负荷患者有强预后预测价值

核心结论

  • PET-CT是FL分期和疗效评估的金标准成像方式
  • PET可指导分期和反应适应治疗,但基线定量PET的作用需进一步明确

研究设计与样本

  • 本 Perspective 文章基于现有研究证据讨论PET在FL治疗决策中的作用

主要发现

  • PET分期较标准CT敏感性更高,真正局限期FL患者结局改善
  • 小数据集提示基线SUVmax高可识别新发组织学转化,但未被GALLIUM研究证实
  • 初诊FL患者中位生存期现在可能超过20年
  • EOI PET对高肿瘤负荷患者无进展生存和总生存有强预测价值

关键数值与推荐

  • 初诊FL患者中位生存期现在可能超过20年

临床怎么用

  • PET用于FL分期和疗效评估
  • EOI PET可作为高肿瘤负荷患者反应适应治疗的平台

局限性

  • 基线定量PET指标作用需进一步明确
  • PET阳性患者生存较差,改善需求未满足
  • 缺乏总生存优势情况下,PET引导治疗决策在COVID-19大流行中更重要

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) is now established as the gold-standard imaging modality for both staging and response assessment in follicular lymphoma (FL). In this Perspective, we propose where PET can, and cannot, guide clinicians in their therapeutic approach. PET at diagnosis and pretreatment is important for staging, with greater sensitivity compared with standard CT, and consequent improved outcomes in truly limited-stage FL. Small data sets suggesting that a high baseline standardized uptake value (SUVmax) identifies de novo histologic transformation (HT) have not been corroborated by data from GALLIUM, the largest prospective study to examine modern therapies for FL. Nonetheless, the role of baseline quantitative PET measures requires further clarification. The median survival of patients with newly diagnosed FL is now potentially >20 years. Treatment of symptomatic FL aims to achieve remission and optimize quality of life for as long as possible, with many patients achieving a "functional cure" at the cost of unwanted treatment effects. Several studies have identified end-of-induction (EOI) PET after initial chemoimmunotherapy in patients with a high tumor burden as strongly predictive of both progression-free and overall survival, and EOI PET is being evaluated as a platform for response-adapted treatment. Unmet needs remain: improving the inferior survival for patients remaining PET positive and quantifying the progression-free survival and time to next treatment advantage, and additional toxicity of anti-CD20 maintenance in patients who achieve complete metabolic remission. In the absence of an overall survival advantage for frontline antibody maintenance, the question of using PET to guide the therapeutic approach is more important than ever in the context of the COVID-19 pandemic.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Trotman J, Pettitt AR. Is it time for PET-guided therapy in follicular lymphoma? Blood. 2022. PMID: 34260714. doi:10.1182/blood.2020008243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。